Építés alatt – nem éles oldal
Belépés
Leállítva2. fázis

Safety and Pharmacodynamics of SHR-1707 in Alzheimer's Disease Patients

A legfontosabb adatok

Ki végzi
Shanghai Hengrui Pharmaceutical Co., Ltd.
Hol
Kína1 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Leállítva
Fázis
2. fázis
Résztvevők
46 fő vett részt
Kezdés
2024. febr. 5.
Befejezés
2026. jan. 30.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
A vizsgált kezelések
  • SHR-1707
  • SHR-1707 placebo
A regiszteradat frissítve
2026. május 13.
Miért állt le
Based on the adjustment of the sponsor's R\&D strategy, it is decided to terminate this study in advance.

Ki vehet részt

Életkor
50 év – 85 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 33 feltétel megnézéseKevesebb

Ki vehet részt

  • Age ≥50 and ≤85 on the date of signing the informed consent, males or females
  • BMI≥18kg/m2 and ≤32 kg/m2, weight ≥45 kg且≤100 kg at screening or baseline;
  • must meet the diagnostic criteria for MCI due to AD or mild AD
  • The total score of HAMD-17 should be ≤10 scores at screening
  • The score of Hachinski ischemic scale should be ≤4 scores at screening
  • amyloid PET scan results from the central laboratory confirmed the presence of pathological changes in AD
  • Agreed to test ApoE genotype
  • Have a stable caregiver; where symptomatic drugs for AD is used, they must be stable for at least 1 months prior to the screening visit

Ki nem vehet részt

  • Patients who had severe trauma or had undergone surgery within 6 months prior to screening, or were scheduled to undergo surgery during the trial
  • History of hypoglycemic coma or uncontrolled diabetes 6 months prior to the screening period
  • Had unstable or clinically significant cardiovascular disease within 1 year prior to the screening period, had or currently has atrial fibrillation
  • Patients with clinically significant systemic immunosuppression due to the persistent effects of immunosuppressive drugs
  • According to the investigators, the subjects were suicidal or had committed suicidal behaviour in the six months before the screening period
  • A woman who is pregnant, or a woman of childbearing potential whose pregnancy test results are positive, or who is breastfeeding; or has a plan to have a child, unwilling or unable to take effective contraceptive measures within 30 days prior to the screening period or six months after the last use of the investigational drug
  • Three months prior to the randomization period or planned to use dual antiplatelet or anticoagulant drugs during the trial
  • Received any passive immunotherapy or other long-acting biologics used to prevent or delay cognitive decline within 3 months prior to screening
  • Cognitive impairment of subjects due to other medical or neurological factors (other than AD)
  • History of stroke or transient ischemic attack, seizures, or other unexplained loss of consciousness within the past year
  • Any psychiatric diagnosis that may interfere with the subject's cognitive assessment
  • Cannot tolerate MRI or has contraindications to MRI, has significant lesions shown on MRI during screening, or has other conditions that the investigator believes may bring a significant risk to the subject
  • History of moderate (3b) or severe renal failure or insufficiency
  • Uncontrolled hypertension: systolic blood pressure > 160mmHg and diastolic blood pressure >100mmHg during screening or baseline
  • History of malignancy within 5 years prior to screening
  • Human immunodeficiency virus antibody (HIV-Ab), treponema pallidum antibody and hepatitis C virus antibody (HCV-Ab) were positive during screening.Hepatitis B active subjects [Hepatitis B virus surface antigen (HBsAg) positive with HBV DNA > upper limit of normal]
  • coagulation disorders
  • Severe visual or hearing impairment, unable to cooperate with the completion of the scale
  • History of drug abuse or addiction
  • Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) exceeding 3 times ULN, or total bilirubin exceeding 2 times ULN
  • 12-lead ECG showed QTcF >450ms for male and >470ms for female during screening
  • Thyroid dysfunction;
  • Folic acid or vitamin B12 below the lower limit of normal
  • Investigators and relevant staff of the research Centre or others directly involved in programme implementation
  • The investigator considers that there are any circumstances that would cause the subject to be unable to complete the study or pose a significant risk to the subject or other factors that would interfere with the subject's ability to complete the study evaluation

Hol van ez a vizsgálat?

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

Evaluate the Safety, Tolerability and Pharmacodynamics of Intravenous Administration of SHR-1707 In Patients with Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease.

A vizsgálat 2 csoportja

  • SHR-1707A vizsgált kezelés
  • SHR-1707 placeboPlacebo, összehasonlításként

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacodynamics of Intravenous Administration of SHR-1707 In Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
A regiszteradat frissítve
2026. május 13.